Biotech entity
pharma is the sole category represented across all 2 tracked stories. CSL Seqirus is most often covered alongside Arcturus Therapeutics, which appears in 1 of these 2 stories. Across a 13-day span, the pace is roughly 1.1 stories per week.
Last mentioned: Mar 14, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 50 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
pharma is the sole category represented across all 2 tracked stories. CSL Seqirus is most often covered alongside Arcturus Therapeutics, which appears in 1 of these 2 stories. Across a 13-day span, the pace is roughly 1.1 stories per week. Source depth averages 2 original sources per story, versus 3.6 across the same-window beat baseline. The 5.5 average consequence score is below the beat benchmark of 6.1 in the same window. CSL Seqirus appears in 2 tracked Biotech stories published from March 2, 2026 through March 14, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 160 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering CSL Seqirus. Shared-story counts are live from our verified record — not editorial picks.
Wholesale egg prices have dropped significantly as the poultry industry recovers from devastating H5N1 outbreaks. However, the biotech sector remains on high alert as researchers and regulators weigh the long-term necessity of mass poultry vaccination and human pandemic preparedness.
Arcturus Therapeutics and Rigel Pharmaceuticals are set to report Q4 2025 results, highlighting a pivotal year for mRNA platform validation and oncology market expansion. Investors are focused on Arcturus's sa-mRNA commercial progress in Japan and Rigel's sales trajectory for its flagship hematology treatments.
CSL Seqirus is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
